Medical Device and Diagnostic Industry: Biodesix Makes the Case for VeriStrat Through New Study

Posted on

[et_pb_section bb_built=”1″][et_pb_row][et_pb_column type=”4_4″][et_pb_text _builder_version=”3.0.82″ background_layout=”light” border_style=”solid” box_shadow_position=”outer”]

“The Biodesix VeriStrat test received an extra dose of validation last week through a 1,048-patient study published in the Oncologist. The study demonstrated the prognostic value of the VeriStrat test in patients with non-small cell lung cancer (NSCLC).”

 

Read the full story. 

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]